Mr. Thomas Smeenk reports

HEMOSTEMIX CONTRACTS PROCONSUL TO RAMP UP ENGAGEMENT WITH NEW INVESTORS

Hemostemix Inc. has engaged ProConsul Capital Ltd. to provide investment marketing consulting services commencing Feb. 6, 2025. In consideration for the services, the company will pay a fee of $6,000/month and has agreed to grant stock options to ProConsul. The number and terms of the stock options will be determined at a later date, and announced by the company. The agreement is renewable on a month-to-month basis unless terminated by either party on 30 days written notice.

About Hemostemix Inc.

Founded in 2003, Hemostemix is a clinical-stage biotechnology company recognized for its patented blood-based stem cell therapeutics platform. Hemostemix is focused on scaling angiogenic, neuronal and cardiomyocyte cell precursors to treat no-option patients worldwide.

We seek Safe Harbor.